The global genomics market size was estimated at USD 12.02 billion in 2016. It is anticipated to progress at a CAGR of 9.7% over the forecast period. Widening base of genomic data pool from genomic research activities is enabling physicians, biologists, and patients to further investigate genetic predisposition to certain diseases. Clinical application of this data pool is estimated to play a vital role in transforming healthcare system with respect to provision of more accurate, effective, and reliable disease management solutions.
Although clinical application of genomic data is at a nascent stage in present, healthcare and research community are making attempts for effective integration of genetic information into clinical workflows. Several clinical centers, such as Stanford Health Care and other cancer research centers, have begun using available genomic information to devise personalized treatment regime. This, in turn, helps in bridging gap between translational research and clinical diagnosis & treatment.
Implementation of human genetic studies into various public health programs such as consumer wellness programs, population screening, and others is expected to increase over the coming years. The programs are mainly aimed at optimizing preventive care for common chronic diseases such as cancer and heart disease.
This is mainly because use of combinational approach of genomics data and clinical data facilitates gaining insights into population health at molecular level. Growing awareness among consumer regarding genetic tests is one of the key trends stoking market growth.
One of the primary factors likely to influence the growth of the market is how much and to what extent will medical community make use of available genomic information in personalized medicine. Scientists are combining data generated from sequencing with diagnostics, which has proven effective in enhancing personalized treatment landscape.
Generation of a large amount of sequencing data is leading to significant growth in the functional genomics segment. Development of high-throughput technologies for gene as well as protein studies has supported the growth of the segment. Progress in the genomic industry from studying individual genes to entire genomes & proteomes within a relatively short time frame reflects the growth of the segment. Integration of high throughput solutions in functional genomics has offered possibility of developing efficacious drugs with fewer adverse effects. Furthermore, use of behavioral genetic tool kits holds a significant potential for evaluation of competing hypotheses regarding modules and peculiarities of particular behavior.
Real-time quantitative PCR has played a vital role in absolute quantification of genetic elements in genomic DNA. This technology has been employed to evaluate the use of tissue genomic DNA as a universal external standard for accelerating quantification of any target sequence in genome of various species. Use of this technology in combination with reverse transcription PCR enables quantification of low-abundance mRNA, which in turn allows researchers to quantify relative gene expression at a particular time. Since this technology is observed to be more sensitive than array technology, when it comes to detection of small changes in gene expression, its adoption rate is estimated to remain high throughout the forecast period.
Miniaturization in instruments used in genomic applications is expected to help the market gain tremendous traction over the coming years. Advantages offered by these instruments include specificity, sensitivity, and automation for development of point-of-care diagnostics. With maturity in development of microfabrication technology, microfluidic systems are likely to be useful for different genomic detections. Major objectives of these miniaturized instruments is development of point-of-care devices. Moreover, rising usage of impedimetric detection is one of the promising factors to rev up adoption of instruments in the market. Advancements in circuits and systems are poised to augur well for the genomics market.
Growing uptake of cloud based solutions, which effectively and robustly manage parallelization and distribution of input data and user code on a large number of computer nodes, are projected to provide a fillip to the market. Cloud computing provides a clear advantage of performing tasks across different parallel computing nodes and processors coupled with significant reduction in the waiting time. Introduction of cloud computing environment for processing NGS generated data has played a pivotal role in the development of the market.
NGS-based services are experiencing upsurge in adoption since its introduction. Demand for these services is anticipated to remain strong throughout the forecast period owing to expansion of end user base.
With decrease in sequencing costs and improvements in informatics, genetic solutions are now widely accessible in various sectors ranging from small labs to large clinical settings. Based on end use, the market has been segmented into pharmaceutical & biotechnology companies, hospitals & clinics, academic & government institutes, clinical research, and other end users. Among these, pharmaceutical and biotechnology companies held the largest share in the market owing to increasing number of genetic research studies that aim at improving drug discovery process and development of efficacious drugs with fewer side effects.
Moreover, biotechnology companies are effectively using gene editing tools to address unmet needs of patients through development of recombinant and genetically engineered products. The others segment, including direct-to-consumers (DTC), agriculture research institutes, and forensic centers, is anticipated to represent a small share in the market. This is primarily because of less and slow usage of genetic tools within these entities. However, in the coming years, this segment is estimated to witness strong growth owing to growing popularity of DTC among consumers, government, and genomic companies.
North America was the leading revenue contributor in 2016. Increasing investment on research by government organizations, rising patient awareness, and availability of sophisticated healthcare infrastructure are promoting technological advancements in the market. Local presence of key players such as Affymetrix, Inc.; Bio-Rad Laboratories, Inc.; Agilent Technologies; GE Healthcare; Illumina, Inc.; Cepheid, Inc.; and Danaher Corporation is also one of the key growth stimulants for the regional market.
Asia Pacific is poised to witness the fastest growth in the coming years. Developing healthcare infrastructure in countries in the region is leading to increase in demand for biomarkers for diagnostics purposes. Rising adoption and awareness regarding genomic technologies for detection, treatment, and prognosis of various genetic disorders such as diabetes and cancer in emerging countries such as China and India are contributing to the growth of the regional market.
There are several interesting human genome sequencing projects being carried out, one of the most recent projects is Genome Asia 100K (GA 100K). Under this project, 100,000 Asians genomes will be sequenced and analyzed, which will help accelerate population-specific medical advances and precision medicine.
Some of the major players in the market are Thermo Fisher Scientific, Inc.; Agilent Technologies; Bio-Rad Laboratories, Inc.; Danaher; BGI; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Pacific Biosciences; Oxford Nanopore Technologies.; 23andMe, Inc.; Foundation Medicine, Inc.; and Myriad Genetics, Inc.
Companies are focusing on offering varied reagents that simplify workflow process. For instance, in January 2017, BD launched Precise WTA Reagents for accurate and simple quantification of genetic information from single cell analysis. Moreover, in July 2016, SGI-DNA, a company involved in synthetic genomics, entered into a distribution agreement with VWR. Under this agreement, VWR provides companies with reagents in North America and Europe.
Thus, high saturation owing to a wide range of reagents & consumables has compelled players to adopt different strategies to stay ahead in the market. Agilent has also broadened its offering of CRISPR RNA libraries for genome-based research.
Base year for estimation
Actual estimates/Historic data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global genomics market report on the basis of technology & application, product & service, end use, and regions:
Product and Service Outlook (Revenue, USD Million, 2014 - 2025)
Consumables & Reagents
Core Genomics Services
Biomarker Translation Services
Application & Technology Outlook (Revenue, USD Million, 2014 - 2025)
Chromatin immunoprecipitation (ChIP & ChIP-Seq)
Methylated DNA immunoprecipitation (MeDIP)
High resolution melt (HRM)
Chromatin accessibility assays
Proteomics tools (2-D PAGE; yeast 2-hybrid studies)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Academic and Government Institutes
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Other End Users
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."